Product
Dalbavancin
Aliases
Dalbavancin single dose, Dalbavancin two dose, Dalvance, Xydalba
Name
DALVANCE
INN Name
Dalbavancin
FDA Approved
Yes
11 clinical trials
1 organization
22 indications
1 document
Indication
Bacterial InfectionsIndication
Staphylococcal Skin InfectionsIndication
DiabetesIndication
InfectionIndication
Osteoarticular infectionIndication
FrostbiteIndication
Staphylococcal BacteraemiaIndication
Prosthesis-related InfectionsIndication
Gram-Positive Bacterial InfectionsIndication
Gram-Positive BacteremiaIndication
Substance Use DisordersIndication
Intravenous Substance AbuseIndication
Bone InfectionIndication
OsteomyelitisIndication
ArthritisIndication
Joint InfectionIndication
Periprosthetic Joint InfectionIndication
Catheter-Related Bloodstream InfectionIndication
Staphylococcus aureus infectionIndication
PeritonitisIndication
Soft Tissue InfectionsClinical trial
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure InfectionsStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections - DALBADIA StudyStatus: Completed, Estimated PCD: 2022-05-31
Clinical trial
Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee ReplacementsStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic AnalysisStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus BacteremiaStatus: Completed, Estimated PCD: 2023-10-06
Clinical trial
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device InfectionsStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive InfectionsStatus: Terminated, Estimated PCD: 2023-10-05
Clinical trial
Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee InfectionsStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Randomized Open-label Controlled Trial Evaluating a Single-dose Intravenous Dalbavancin Versus Standard Antibiotic Therapy During Catheter-related Bloodstream Infections Due to Staphylococcus AureusStatus: Recruiting, Estimated PCD: 2025-09-23
Clinical trial
Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis PatientsStatus: Terminated, Estimated PCD: 2023-12-31
Clinical trial
An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic TherapyStatus: Withdrawn, Estimated PCD: 2025-04-01
Document
DailyMed Label: DALVANCEOrganization
Allergan, Inc.